Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

CMB.Tech NV stock closes up 4% in Brussels — dividend timing, “freeze period” and next dates in focus

CMB.Tech NV stock closes up 4% in Brussels — dividend timing, “freeze period” and next dates in focus

BRUSSELS, Jan 7, 2026, 18:20 CET — Market closed CMB.Tech NV shares closed up 4.1% at 8.89 euros in Brussels on Wednesday, taking their gain over the past five sessions to about 9.6%. The stock finished near a one-week high after the shipping group flagged the trading and payment timetable for an interim dividend. MarketScreener The dates matter now because the record date — when share ownership is checked for dividend eligibility — falls on Wednesday for the Brussels and New York lines, while the company has also imposed a short “freeze period” that temporarily blocks share repositioning between registers.
7 January 2026
···
Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

Legend Biotech (LEGN) stock jumps after Oppenheimer starts coverage with $75 target

New York, January 7, 2026, 12:32 (EST) — Regular session Shares of Legend Biotech Corp rose 7.4% to $22.53 in midday trading on Wednesday after Oppenheimer initiated coverage with an “Outperform” rating and set a $75 price target, according to MarketBeat. StreetInsider said Oppenheimer analyst Trevor Allred authored the initiation note. MarketBeat Why it matters now: Legend’s stock has been under pressure and touched a 52-week low of $21.16 earlier this week, keeping investors sensitive to any shift in the narrative around its lead product, Carvykti. Carvykti is a CAR‑T therapy — a personalized cancer treatment that uses a patient’s
7 January 2026
·····
Nokia stock jumps in New York after Kepler flips to “buy” as earnings loom

Nokia stock jumps in New York after Kepler flips to “buy” as earnings loom

NEW YORK, Jan 7, 2026, 12:25 EST — Regular session Nokia Oyj’s U.S.-listed shares climbed 5.9% to $6.86 in midday trade on Wednesday after Kepler Cheuvreux upgraded the Finnish telecom equipment maker to “buy,” according to StreetInsider. StreetInsider.com The call landed after a roughly 15% pullback from recent highs, which Kepler said had opened a better entry point. The broker raised its target price to 6.60 euros from 5 euros and called Nokia’s valuation “rather reasonable” at about 13 times its 2026 estimated EBIT — earnings before interest and taxes. Investing.com That matters now because Nokia is heading into its
7 January 2026
····
Firefly Aerospace stock jumps as traders look past fresh class-action reminders

Firefly Aerospace stock jumps as traders look past fresh class-action reminders

NEW YORK, Jan 7, 2026, 12:14 (EST) — Regular session Firefly Aerospace Inc shares rose on Wednesday, swinging sharply after the open even as new law-firm notices about a securities class-action lawsuit spread across newswires. The stock was up 8.5% at $28.69, after trading as low as $25.39 and as high as $29.00. The move matters because Firefly has been trading like a headline stock since its 2025 listing, and the latest legal reminders land days before a Jan. 12 deadline for investors to seek lead-plaintiff status in the case — the shareholder who would represent the class and direct
7 January 2026
·····
Apellis stock jumps nearly 8% as investors look to JPM healthcare update

Apellis stock jumps nearly 8% as investors look to JPM healthcare update

New York, Jan 7, 2026, 12:14 PM EST — Regular session Apellis Pharmaceuticals shares rose nearly 8% on Wednesday, outperforming the broader market as traders positioned ahead of the company’s scheduled appearance at next week’s J.P. Morgan Healthcare Conference. investors.apellis.com The Waltham, Massachusetts-based drugmaker said on Monday it will present on Jan. 12 at 11:15 a.m. PT, with a live webcast posted to its investor site and a replay available afterward. Big healthcare conferences often bring fresh guidance, new trial details or partnering chatter — and the tape tends to price that in early. investors.apellis.com Apellis was last up $1.91
7 January 2026
·····
DHT Holdings stock jumps as tanker shares rally on Venezuela oil shake-up

DHT Holdings stock jumps as tanker shares rally on Venezuela oil shake-up

NEW YORK, Jan 7, 2026, 11:52 (EST) — Regular session Shares of DHT Holdings, Inc. rose 6.6% to $12.81 on Wednesday, extending a broad rally in U.S.-listed tanker stocks during the regular session. Frontline gained about 8%, Teekay Tankers added about 9%, Scorpio Tankers rose about 5% and Nordic American Tankers climbed about 6.7%. The move matters because DHT is a pure-play crude tanker owner, with most of its fleet made up of VLCCs — very large crude carriers that move oil on long-haul routes. That puts the stock close to the freight market: when spot rates (short-term charter prices)
7 January 2026
········
Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention NEW YORK,

Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention NEW YORK,

Jan 7, 2026, 11:43 EST — Regular session Bloom Energy Corp (NYSE: BE) shares rose 8.1% to $111.38 on Wednesday, lifting off an intraday low of $100.87, as investors refocused on a new $600 million bank line and a large fuel-cell microgrid purchase linked to Quanta. The stock hit an intraday high of $111.41 and traded more than 8.3 million shares by late morning, keeping the $100 level in play for traders after the early slide. The move matters because Bloom has become a sensitive read-through on on-site power demand, a corner of the market that has drawn attention as
7 January 2026
·····
Praxis Precision stock rises as $575 million share sale clears at $260

Praxis Precision stock rises as $575 million share sale clears at $260

NEW YORK, Jan 7, 2026, 12:02 PM EST — Regular session Praxis Precision Medicines shares rose about 6% on Wednesday after the biotech priced a $575 million public offering overnight, even as the deal came at a discount to the prior close. GlobeNewswire The Boston-based company late Tuesday set the offering at $260 per share for 2.212 million shares, and gave underwriters a 30-day option to buy up to 331,800 more shares. The deal is expected to close on or about Jan. 8, the company said. GlobeNewswire The stock was last at about $289.5 in midday trading, versus Tuesday’s close
7 January 2026
·····
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

New York, Jan 7, 2026, 11:50 a.m. EST — Regular session Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort. The agreement matters because it puts near-term cash on the table for a clinical-stage biotech and suggests its intellectual property has value beyond its own pipeline, at a moment when markets are quick to price any edge in the crowded GLP-1 weight-loss race. A Form 8-K filing showed the company’s Gasherbrum Bio
7 January 2026
···
Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

Bloom Energy stock jumps as $600 million Wells Fargo credit line and $502 million Quanta microgrid deal draw fresh attention

NEW YORK, Jan 7, 2026, 11:43 EST — Regular session Bloom Energy Corp (NYSE: BE) shares rose 8.1% to $111.38 on Wednesday, lifting off an intraday low of $100.87, as investors refocused on a new $600 million bank line and a large fuel-cell microgrid purchase linked to Quanta. The stock hit an intraday high of $111.41 and traded more than 8.3 million shares by late morning, keeping the $100 level in play for traders after the early slide. The move matters because Bloom has become a sensitive read-through on on-site power demand, a corner of the market that has drawn
7 January 2026
·····
Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

New York, Jan 7, 2026, 10:56 EST — Regular session Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11 and $43.74 so far in the session, with nearly 1.0 million shares traded. Why it matters now: the move builds on Tuesday’s 22% gain and keeps Regencell near the top of the day’s high-volatility names, even by small-cap standards. The stock closed at $33.03 on Tuesday after trading as high as $35.68, following a $27.00 close on Monday. StockAnalysis The
7 January 2026
··
Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

Abivax stock jumps 7% on Nasdaq — here’s what’s moving ABVX and what’s next

New York, Jan 7, 2026, 11:10 EST — Regular session Shares of Abivax SA jumped 7.3% to $127.75 in morning trading on Wednesday, after touching a session high of $128.87 and a low of $119.48. Trading volume topped 700,000 shares. The French biotech’s U.S.-listed stock has become a fast-moving name for healthcare traders, in part because its valuation rests on a single late-stage drug program. Its American depositary shares, or ADSs, are U.S.-traded certificates that represent ownership of a foreign company’s shares. Abivax is developing obefazimod, an oral treatment candidate for ulcerative colitis, a chronic inflammatory bowel disease. The company
7 January 2026
·····
1 … 383 384 385 386 387 … 882

Stock Market Today

South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop